TY  - JOUR
AU  - Kessler, Tobias
AU  - Schrimpf, Daniel
AU  - Doerner, Laura
AU  - Hai, Ling
AU  - Kaulen, Leon
AU  - Ito, Jakob
AU  - van den Bent, Martin
AU  - Taphoorn, Martin
AU  - Brandes, Alba A
AU  - Idbaih, Ahmed
AU  - Dômont, Julien
AU  - Clement, Paul M
AU  - Campone, Mario
AU  - Bendszus, Martin
AU  - von Deimling, Andreas
AU  - Sahm, Felix
AU  - Platten, Michael
AU  - Wick, Wolfgang
AU  - Wick, Antje
TI  - Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial.
JO  - Clinical cancer research
VL  - 29
IS  - 19
SN  - 1078-0432
CY  - Philadelphia, Pa. [u.a.]
PB  - AACR
M1  - DKFZ-2023-01512
SP  - 3892-3900
PY  - 2023
N1  - #EA:B320# / 2023 Oct 2;29(19):3892-3900
AB  - The EORTC-26101 study was a randomized phase 2 and 3 clinical trial of bevacizumab in combination with lomustine versus lomustine alone in progressive glioblastoma. Other than for progression-free survival (PFS), there was no benefit from addition of bevacizumab for overall survival (OS). However, molecular data allows for the rare opportunity to assess prognostic biomarkers from primary surgery for their impact in progressive glioblastoma.We analyzed DNA methylation array data and panel sequencing from 170 genes of 380 tumor samples of the EORTC-26101 study. These patients were comparable to the overall study cohort in regards of baseline characteristics, study treatment and survival.295/380 (78
LB  - PUB:(DE-HGF)16
C6  - pmid:37494539
DO  - DOI:10.1158/1078-0432.CCR-23-0926
UR  - https://inrepo02.dkfz.de/record/277801
ER  -